(Q36463238)

14 August 2017

Intermittent androgen suppression for rising PSA level after radiotherapy (English)

1 reference

14 August 2017

0 references

Emma Hall

18

0 references

Padraig Warde

object named as

Padraig Warde

11

0 references

Laurence Klotz

21

object named as

Laurence Klotz

1 reference

14 August 2017

16

Fred Saad

1 reference

14 August 2017

Juanita M Crook

1

1 reference

14 August 2017

Christopher J O'Callaghan

2

1 reference

14 August 2017

Graeme Duncan

3

1 reference

14 August 2017

David P Dearnaley

4

1 reference

14 August 2017

Celestia S Higano

5

1 reference

14 August 2017

Eric M Horwitz

6

1 reference

14 August 2017

Eliot Frymire

7

1 reference

14 August 2017

Shawn Malone

8

1 reference

14 August 2017

Joseph Chin

9

1 reference

14 August 2017

Abdenour Nabid

10

1 reference

14 August 2017

Thomas Corbett

12

1 reference

14 August 2017

Steve Angyalfi

13

1 reference

14 August 2017

S Larry Goldenberg

14

1 reference

14 August 2017

Mary K Gospodarowicz

15

1 reference

14 August 2017

John P Logue

17

1 reference

14 August 2017

Paul F Schellhammer

19

1 reference

14 August 2017

Keyue Ding

20

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 September 2012

1 reference

The New England Journal of Medicine

14 August 2017

1 reference

14 August 2017

367

1 reference

14 August 2017

895-903

1 reference

14 August 2017

10

1 reference

Endocrine complications of androgen-deprivation therapy in men with prostate cancer.

14 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3521033

Measurements of tissue polypeptide-specific antigen and prostate-specific antigen in prostate cancer patients under intermittent androgen suppression therapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3521033

Intermittent androgen deprivation after PSA-complete response as a strategy to reduce induction of hormone-resistant prostate cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3521033

Power function arguments in support of an alternative approach for analyzing management trials

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3521033

A Multiple Testing Procedure for Clinical Trials

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3521033

Interpreting the significance of changes in health-related quality-of-life scores.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3521033

External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3521033

Long-term effects of intermittent androgen suppression on testosterone recovery and bone mineral density: results of a 33-month observational study.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3521033

Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3521033

Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3521033

Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3521033

The Effects of Combined Androgen Blockade on Cognitive Function During the First Cycle of Intermittent Androgen Suppression in Patients With Prostate Cancer

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3521033

Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3521033

Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3521033

Influence of Androgen Suppression Therapy for Prostate Cancer on the Frequency and Timing of Fatal Myocardial Infarctions

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3521033

Intermittent androgen suppression in the management of prostate cancer

4 December 2018

1 reference

12 December 2020

Clinical Experience with Intermittent Androgen Suppression in Prostate Cancer: Minimum of 3 Years' Follow-Up

1 reference

12 December 2020

Intermittent androgen suppression for prostate cancer: Canadian Prospective Trial and related observations

1 reference

12 December 2020

Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer

1 reference

12 December 2020

Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma

1 reference

12 December 2020

Intermittent endocrine therapy for advanced prostate cancer

1 reference

12 December 2020

Stopping rules for clinical trials incorporating clinical opinion

1 reference

12 December 2020

Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen

1 reference

12 December 2020

Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model

1 reference

12 December 2020

Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study

1 reference

12 December 2020

Intermittent endocrine therapy of prostate cancer

1 reference

12 December 2020

A pilot study of intermittent androgen deprivation in advanced prostate cancer

1 reference

12 December 2020

Identifiers

DOI

10.1056/NEJMOA1201546

1 reference

14 August 2017

1 reference

14 August 2017

1 reference